reason report
expect busi outlook intact o/p
bottom line alexion report financi result
consensu revenu ep disclos
posit top-line data pnh switch studi
top-line result consequ higher expect uptak
strensiq quarter despit narrow miss soliri headwind
prior year one time item off-set strong mg launch
trajectori show earli sign durabl increment growth
driver revenu alexion also benefit lower expect
non-gaap expens quarter boost bottom
line beat alexion revis full-year guidanc rais
total revenu forecast increas ep guidanc due lower
anticip effect tax rate final compani updat time
file mid year posit nmo phase trial year
end neg investor react posit reassur oper
result de-risk stock final seen
revers troubl trajectori last two month
base result manag updat guidanc
increas revenu forecast
increas oper expens futur year
revis ep forecast reduc futur year revenu
forecast line recent consensu ep estim
also consensu beyond revis price target
base new forecast chang peer
compani multipl reiter outperform rate alexion
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings
compani inform leerink partner llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target rate stock
outperform alexion lead independ compani develop commerci
treatment ultra-rar disord complement system revenu today come
soliri approv two differ rare diseas indic believ
alexion increas current revenu run rate complement franchis
competit threat soliri overst view given long safeti
efficaci histori soliri well alexion progress develop improv version
product greater potenc longer half-lif conveni dose beyond soliri alexion
still earli phase launch two addit rare diseas medicin kanuma
strensiq expect contribut approxim combin revenu
alexion maintain reason financi disciplin expect oper margin
bounc back better drop acquisit
synageva cost two product launch alexion remain
one fastest grow busi biopharmaceut durabl larg molecul
protein therapi believ recov multipl come quarter fail
trade discount reason cautiou outlook could becom one
target expect increasingli consolid industri
revenu slightli ahead consensu despit soft soliri sale row global sale
soliri qoq slightli consensu
forecast sale soliri neg affect headwind due clinic
trial enrol pnh ahu well comparison boost one
time item addit ex-us/eu/asia sale impact neg time order
latin america result declin yoy sale region although alexion insist
face busi usual brazil latam market sale strensiq
beat consensu estim due part benefit
chang distribut us kanuma revenu came
consensu estim
gmg launch show strong uptak alexion explicitli provid sale soliri
myasthenia gravi indic indic mg patient soliri us
end march trend suggest addit patient may start therapi
month captur rate turn newli refer patient compani
reimburs hub seem also suggest alexion could easili add
addit patient per month base analysi estim mg contribut
soliri sale could total even materi sale
pro-forma ep beat wide margin due slowdown opex gross margin
consist consensu total oper expens
oper incom consensu
forecast oper margin improv compar consensu
estim compani effect tax rate
quarter prior guidanc pro-forma
ep qoq yoy beat consensu estim
guidanc revis higher sale lower tax higher ep follow
oper result alexion revis full-year guidanc revenu tax rate ep
compani anticip total product revenu
soliri revenu guidanc increas
metabol revenu increas compani reiter
view underli revenu growth soliri exist non-mg indic
low doubl digit although steer investor expect high singl digit
core busi appear continu strong ramp mg indic well
sale mg ex us market flagship product could easili grow rang
oper margin guidanc remain year like increas
half support recent wilson diseas acquisit alexion lower tax rate
guidanc previous revis ep guidanc
previous revis ep guidanc slightli consensu estim
materi revis estim
surpris investor includ result pnh switch studi press releas
morn alexion state achiev primari endpoint studi
demonstr non-inferior soliri reduc ldh appear alexion
unfortun narrowli miss mark superior soliri less lower bound
confid interv nevertheless combin posit result
pnh trial clearli demonstr numer clinic trend favor soliri
compani includ data us eu bla file import
takeaway data provid morn includ numer superior
primari key secondari endpoint lack discontinu anti-drug antibodi
meningococc infect seen trial arm
catalyst slowdown pnh studi report next pipelin catalyst
alexion regulatori file data soliri neuromyel optica nmo
develop latter half alexion push back origin
time report nmo data expect top-line data avail
compani state call prevent studi fulli enrol howev event-
driven studi infer relaps rate control arm slower anticip
prior nmo data enrol on-going atyp hemolyt urem syndrom
ahu phase studi complet top-line data expect year
clinic develop subcutan formul also expect begin
pharmacokinet bridg phase studi late trial expect support
registr subcutan deliv pnh ahu phase enrol
recent acquir wilson diseas on-going
updat forecast reduc price reiter op follow result
recent quarter made updat revenu earn forecast
better reflect compani oper go forward result chang
adjust price target previous increas sale
decreas sale forecast strensiq futur year due
slightli slower ex-u growth total revenu forecast increas futur year
roughli in-lin recent consensu also increas oper
expens estim reflect addit expenditur result
develop updat pro-forma dilut ep estim decreas
futur year recent consensu modestli
consensu outer year addit account decreas cash reflect
close wilson transact although includ
program revenu forecast stage base chang compani model
peer compani multipl reduc price target maintain
outperform rate alexion stock
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
discount cash flow dcf use rel multipl similar growth compani
ep appli ep estim alexion give fair valu
stock use expect ep compound-annual-growth-rate alexion period
current averag ratio larg molecul large-cap biotech give ep
multipl discount multipl compress alexion
appli ep estim give fair valu final dcf use
termin growth rate post give current valu averag
three valuat methodolog new pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product final brand gener competitor
product soliri come market captur greater share caus greater market price
disrupt current expect futur outlook valuat would undermin
opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica
myasthenia gravi novel rare diseas medicin time horizon forecast
sale non-gaap
share count period dilut
guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time
complet enrol
phase ahu
result pivot ahu
result pivot phase
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
million
leerink partner research compani file
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target alexion
method today larg cap brand biopharma futur ep multipl ep
leerink estimate earn
current averag larg cap biopharma multipl ep
leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag larg molecul larg cap biopharma co
impli ep multipl discount vs full multipl
averag method
leerink partner research compani file factset
